key: cord-0985186-pp6se1cr
authors: Placke, J.-M.; Reis, H.; Hadaschik, E.; Roesch, A.; Schadendorf, D.; Stoffels, I.; Klode, J.
title: Covid-19 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up - a monocenter study
date: 2021-06-26
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.06.023
sha: a53e0d75e2d9a72a814be516808a4cfafae32c3a
doc_id: 985186
cord_uid: pp6se1cr

INTRODUCTION: The Covid-19 pandemic has changed the lives of people around the world. Fortunately, sufficient vaccines are now available. Local reactions with ipsilateral lymphadenopathy are among the most common side effects. We investigated the impact of lymphadenopathy after Covid-19 vaccination on the value of ultrasound in tumor patients. PATIENTS AND METHODS: Patients with melanoma or merkel cell carcinoma were included who underwent lymph node excision and received Covid-19 vaccination within 6 weeks before surgery. The consistency of the preoperative ultrasound findings with the histopathologic findings was investigated. RESULTS: Eight patients were included (two Merkel cell carcinoma and six melanoma patients) who underwent lymph node excision between April 16, 2021, and May 19, 2021, and had previously received Covid-19 vaccination. In three of the eight patients (one Merkel cell carcinoma and two melanoma patients), lymph node metastases were erroneously diagnosed preoperatively during tumor follow-up with physical examination, ultrasound, and or FDG PET/CT. In these three patients, the suspected lymph node metastases were located in the left axilla after Covid19 vaccination in the left upper arm, which resulted in selective lymph node removal in two patients and complete lymphadenectomy in one patient. CONCLUSION: Covid-19 vaccine-associated lymphadenopathy is expected to be observed much more frequently in the near future due to increasing vaccination rates. This cause of lymphadenopathy, which may in ultrasound as well as in FDG PET/CT resemble lymph node metastases, must be considered, especially in oncologic patients undergoing tumor follow-up. In addition, Covid-19 vaccination should be given as far away as possible from an underlying primary on the contralateral side to avoid oncologic misdiagnosis followed by malpractice.

The introduction of modern systemic therapies such as immune checkpoint blockade has led to a significant improvement in the prognosis of tumor patients with advanced skin tumors for example melanoma, Merkel cell carcinoma, and squamous cell carcinoma [1] [2] [3] . However, early detection of metastases is of crucial importance for patient outcome. Currently, computed tomographic and magnetic resonance techniques are used as standard of care in suspected distant metastases and in the follow-up of skin cancer patients [4] [5] [6] . As another important method lymph node ultrasound with transducers of 7.5-18 Mhz has been successfully used for many years for the detection of metastases in primary spread diagnostics as well as in the follow-up of aggressive tumors such as melanoma [7] . Ultrasound has a higher sensitivity and specificity with regard to the question of lymph node metastases than the other radiological imaging procedures [8] . The Covid-19 pandemic has been raging worldwide since late 2019, with more than 160 million people infected and more than 3.5 million people who have died so far [9] . Fortunately, several vectorbased and mRNA vaccines have become available in recent months that provide adequate protection against infection [10] . All Covid-19 vaccines licensed in Europe and the United States show good patient safety. Patients often experience modest systemic side effects after Covid-19 vaccination, such as fatigue, fever, chills, headache, or local side effects such as swelling at the injection site. Younger patients seem to be more affected by side effects [11] . Another common side effect after Covid-19 vaccination is ipsilateral lymph node swelling, with recent reports of increased FDG uptake on PET-CT being observed in patients up to 6 weeks after vaccination [12] . Furthermore, sonographically detectable lymphadenopathy after Covid-19 vaccination has already been reported in a recent case report [13] . The following work aims at investigating the impact of Covid-19 vaccination on the validity of lymph node ultrasound in primary spread diagnosis and follow-up in skin cancer patients.

J o u r n a l P r e -p r o o f

The study included patients with histologically confirmed melanoma or merkel cell carcinoma who underwent sentinel lymph node biopsy, selective lymph node extirpation, or complete lymph node dissection. Only patients who have received The respective index (ratio of maximal and minimal lymph node diameters) was calculated for suspicious lymph nodes. Lymph nodes were considered suspicious of malignancy when at least one of the following criteria was applied: Solbiati−Vasallo index less than two, predominance of low echogenicity of the whole lymph node structure, lymph node center with low echogenicity, or asymmetric regions with low echogenicity in the lymph node margin. The Doppler technique was only used to distinguish blood vessels and other low echogenic structures.

For histopathological examination, standard staining consisting of hematoxylin and eosin staining was performed. In addition, immunohistochemical workup of lymph Histopathological lymph node specimens were digitized with the Aperio AT2 wholeslide scanner (Leica, Wetzlar, Germany) at 20x resolution.

Statistical analysis was performed with SPSS Statistics (Version 27, IBM Corp.;

Armonk, NY). For statistical testing, the chi-suare test and Mann-Whitney U test were performed. P-value of <0.05 was considered statistically significant. Table 1) .

In the present study, five patients underwent routine ultrasound examination prior to sentinel lymph node sampling; here, three patients showed unremarkable lymph nodes preoperatively and histopathological evaluation did not reveal evidence of metastases. In the other two patients, malignancy could not be excluded with certainty on ultrasound, and targeted lymph node removal was performed in addition to sentinel lymph node sampling, each of which showed evidence of metastases. 

In this study, we describe for the first time to the best of our knowledge sonographically detectable lymph node changes after Covid-19 vaccination in skin cancer patients during tumor follow-up. Lymph node changes resembling lymph node metastases in terms of enlargement and peripheral vascularization occurred relatively frequently in patients, especially after inoculation into the left upper arm in the area of the left axilla. The time interval between vaccination and ultrasound did not appear to play a significant role, although in one patient vaccination had occurred 50 days before the abnormal ultrasound. This observation is consistent with the results of a recent radiological study, which showed that increased FDG uptake on PET/CT was still detectable in ipsilateral lymph node stations in patients vaccinated with Covid-19 up to 70 days after vaccination [12] . Histologically, one of the patients whose lymph nodes were misjudged to be malignant preoperatively showed marked follicular hyperplasia in all lymph nodes. Marked reactive follicular hyperplasia of the lymph nodes is otherwise frequently observed in the context of infections such as syphilis, toxoplasmosis, HIV, infectious mononucleosis or in the context of autoimmune diseases such as rheumatoid arthritis or Sjögren's syndrome [16] .

Interestingly, another patient whose lymph node was misclassified as malignant showed histopathologically a lymphofollicular hyperplasia and pronounced sarcoidosis-like lympadenopathy. The granulomatous changes can be triggered by activated T-lymphocytes and macrophages through their secretion of interferon gamma, TNF-α and IL-12 [17] . Granulomatous lymph node changes have also been described extensively in patients under immune checkpoint blockade therapy [18, 19] .

Our patient was under adjuvant therapy with BRAF and MEK inhibition, granulomatous changes are not typical for this therapy. It should be noted that in rare cases sarcoidosis is also induced by targeted therapy with BRAF and MEK inhibition, in which case mainly the hilar lung lymph nodes are affected [20] .

Of course, our study has some limitations such as the small number of cases. 

Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma

Comparison of the diagnostic accuracy of whole-body MRI and whole-body CT in stage III/IV malignant melanoma

Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs

Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. The Lancet Oncology

Contemporary Diagnostic Imaging Modalities for the Staging and Surveillance of Melanoma Patients: a Meta-analysis

WHO, World Health Organization Coronavirus (COVID-19) Dashboard

COVID-19 vaccines: where we stand and challenges ahead

Safety and Immunogenicity of Two RNA-Based Covid-19

Vaccine Candidates

Prevalence of Increased FDG PET/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA COVID-19 Vaccination

Lymphadenopathy Associated With the COVID-19 Vaccine. Cureus

Differentiation of benign from malignant superficial lymphadenopathy: the role of high-resolution US. Radiology, 1992

Improved Characterization of Reactive and Malignant Lymph Nodes Using Contrast-Enhanced Ultrasound

Granuloma formation, implications for the pathogenesis of vasculitis

Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors

Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab

Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma

P. served as consultant and/or has received honoraria from Bristol-Myers Squibb and Novartis, and has received travel support from Bristol-Myers Squibb

reported grants and or personal fees from Novartis, LaVision Bio Tec and Sastomed

reported grants from Novartis, Bristol Myers Squibb, and Adtec; personal fees from Merck Sharp & Dohme; and nonfinancial support from Amgen

received grants and other support from Bristol-Myers Squibb, personal fees from

Squibb during the conduct of the study; personal fees from Amgen

personal fees from Boehringer Ingelheim; personal fees from InFlarX; personal fees and other support from Roche; grants, personal fees and other support from Novartis

personal fees from Incyte; personal fees and other support from Regeneron; personal fees from 4SC; personal fees from Sanofi; personal fees from Neracare; personal fees from Pierre-Fabre; personal fees and other support from Merck-EMD; personal fees from Pfizer; personal fees and other support from Philiogen; personal fees from Array

is on the advisory board of Bristol-Myers Squibb, received honoraria from Roche and Bristol-Myers Squibb, received travel support from Philips

received grants from Bristol-Myers Squibb and holds shares of Bayer